New Risk • Aug 04
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Reported Earnings • Aug 04
Second quarter 2026 earnings released: US$0.28 loss per share (vs US$0.23 profit in 2Q 2025) Second quarter 2026 results: US$0.28 loss per share (down from US$0.23 profit in 2Q 2025). Revenue: US$76.4m (down 28% from 2Q 2025). Net loss: US$3.10m (down 225% from profit in 2Q 2025). Revenue is expected to decline by 9.1% p.a. on average during the next 2 years, while revenues in the Personal Products industry in the United Kingdom are expected to grow by 4.1%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance. Announcement • Aug 04
Medifast, Inc. Provides Earnings Guidance for the Third Quarter 2026 and Full Year 2026 Medifast, Inc. provided earnings guidance for the third quarter 2026 and full year 2026. The company expected third quarter 2026 revenue to be in the range of $60 million to $80 million and third quarter 2026 loss per share to be in the range of $0.15 to $0.65. This excludes any one-time costs associated with the execution of the company's Catalyst initiatives.
The company expected full year 2026 revenue to be in the range of $270 million to $300 million and full year 2026 loss per share to range from $0.25 to $1.75. New Risk • Aug 04
New major risk - Revenue and earnings growth Earnings have declined by 54% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 54% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (US$99.9m market cap). New Risk • Jul 24
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$96.9m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (US$96.9m market cap). Announcement • Jul 21
Medifast, Inc. to Report Q2, 2026 Results on Aug 03, 2026 Medifast, Inc. announced that they will report Q2, 2026 results After-Market on Aug 03, 2026 Announcement • Jul 17
Medifast Launches Trilivy Comprehensive Metabolic Health System and Introduces Trilivy Reset Fueling Line Enhanced with Metavantage Technology Medifast, Inc. announced the launch of Trilivy, a comprehensive metabolic health system uniquely designed to support healthy lifestyle change. The launch also introduces newly formulated meal replacements, including the Trilivy Reset Fueling line enhanced with MetaVantage Technology, a platform of proprietary ingredient formulas intended to optimize metabolism by unlocking key metabolic pathways. The launch of Trilivy marks a major corporate transformation, and the beginning of a new era focused on optimal metabolic health. The transition from OPTAVIA to a new brand with the launch of Trilivy represents an evolution of the company’s vision, expanding beyond traditional weight loss to address the broader metabolic health challenges impacting more than 90% of U.S. adults. At the center of the system is Metabolic Synchronization, the company’s breakthrough science that reverses metabolic dysfunction with a targeted reset of the body’s metabolism through three key mechanisms: Burn: Targets visceral fat — the bad fat stored around organs and muscles — achieving a 14% reduction in visceral fat in just 16 weeks. Preserve: Helps retain 98% of lean mass, supporting strength, energy, and mobility during weight loss. Protect: Supports healthy muscle to help restore the body’s natural ability to maintain an active metabolism, optimize energy use, and regulate body weight. The system is structured across three phases: Phase 1: Reset. Reverse metabolic dysfunction and reset metabolism. Phase 2: Refine. Improve metabolic flexibility and refine body composition. Phase 3: Renew. Optimize metabolic health and support healthspan. Accompanying the brand launch is the Trilivy Reset Fueling line enhanced with MetaVantage Technology, which further supports metabolic health by helping reduce waist circumference while also supporting normal fat metabolism and healthy insulin function. Clinical research has shown individuals using the company’s coach-supported program lost up to 10x more weight and 17x more fat than those trying to lose weight on their own. In a clinical study, 98% of lean mass was retained and individuals experienced a reduction of 14% visceral adiposity [visceral fat] on the Optimal Weight 5 & 1 Plan at 16 weeks. In a clinical study, individuals on the Reset Plan with support of a Trilivy coach successfully lost 10x more weight and 17x more fat than those who tried to lose weight on their own. Announcement • Jun 02
Medifast, Inc. Announces Resignation of Jason L. Groves from Chief Legal Officer & Corporate Secretary, Effective May 29, 2026 Medifast, Inc. reported that Jason L. Groves, Esq., the Chief Legal Officer & Corporate Secretary of Medifast, Inc., tendered his resignation from the Company. The employment relationship terminated effective May 29, 2026. Mr. Groves' departure was not the result of any disagreement with the Company nor any issue related to the Company's operations, policies or practices. In connection with Mr. Groves' departure, the Company has commenced a search for a permanent replacement. Announcement • May 06
Medifast, Inc. Provides Earnings Guidance for the Second Quarter of 2026 Medifast, Inc. provided earnings guidance for the second quarter of 2026. The company expects second quarter 2026 revenue to be in the range of $60 million to $80 million and second quarter 2026 loss per share to be in the range of $0.50 to $1.00. Reported Earnings • May 06
First quarter 2026 earnings released: US$0.19 loss per share (vs US$0.071 loss in 1Q 2025) First quarter 2026 results: US$0.19 loss per share (further deteriorated from US$0.071 loss in 1Q 2025). Revenue: US$76.0m (down 34% from 1Q 2025). Net loss: US$2.12m (loss widened 175% from 1Q 2025). Revenue is expected to decline by 17% p.a. on average during the next 2 years, while revenues in the Personal Products industry in the United Kingdom are expected to grow by 3.4%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance. New Risk • May 05
New major risk - Revenue and earnings growth Earnings have declined by 47% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 47% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change). Announcement • Apr 21
Medifast, Inc. to Report Q1, 2026 Results on May 04, 2026 Medifast, Inc. announced that they will report Q1, 2026 results After-Market on May 04, 2026 Announcement • Apr 07
Medifast, Inc., Annual General Meeting, May 19, 2026 Medifast, Inc., Annual General Meeting, May 19, 2026. Location: 1000 aliceanna street, maryland 21202, baltimore United States Announcement • Mar 20
Jeffrey Brown and Michael Hoer Does Not Stand for Reelection as Directors of Medifast, Inc Medifast, Inc. announced the company's Board of Directors has agreed to nominate Parsa Kiai and Jeff Rose from Steamboat Capital Partners LLC as independent director candidates to stand for election at the company’s 2026 Annual Meeting of Stockholders, which is provisionally scheduled for May 19, 2026. These nominations are pursuant to a Cooperation Agreement entered into between the company and Steamboat Capital, which beneficially owns above 5% of the company’s outstanding shares. The Board of Directors has determined that Medifast’s directors Jeffrey Brown and Michael Hoer will not stand for reelection. Medifast Chairman & Chief Executive Officer Dan Chard will continue in his current role, and as previously announced, will step down as CEO on June 1, 2026, while remaining Chairman. Nicholas Johnson, President of Medifast, is expected to succeed Dan Chard as CEO following his departure. New Risk • Mar 13
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$98.3m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 25% per year for the foreseeable future. Minor Risk Market cap is less than US$100m (US$98.3m market cap). Announcement • Feb 20
Medifast Announces OPTAVIA's Comprehensive Metabolic Health System Is Available for Reimbursement on Select Insurance Plans Using Health Savings Accounts and Flexible Spending Accounts Medifast announced that OPTAVIA’s comprehensive metabolic health system is available for reimbursement on select insurance plans using Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA). OPTAVIA clients may be able to save up to 40% on program costs by working with their medical provider and insurance administrator to use pre-tax medical funds, offering accessibility for those prioritizing their metabolic health. OPTAVIA is designed to address these challenges head-on, combining a science-backed system with coaching to guide clients toward improvements in their metabolic health, targeting the root cause of metabolic dysfunction. OPTAVIA’s approach is rooted in our breakthrough science, Metabolic Synchronization™, which resets the body’s metabolism through healthy, quality weight loss, targeting visceral fat reduction, preserving lean mass and protecting healthy muscle. Using the science of Metabolic Synchronization, Medifast plans to launch a new system in 2026 featuring products that incorporate clinically studied ingredients designed to further support metabolic health, marking the next step in the company’s ongoing commitment to providing solutions that adapt to every stage of the health journey. In a clinical study, 98% of lean mass was retained and individuals experienced a reduction of 14% visceral adiposity [visceral fat] on the Optimal Weight 5 & 1 Plan® at 16 weeks. Reported Earnings • Feb 18
Full year 2025 earnings released: US$1.70 loss per share (vs US$0.19 profit in FY 2024) Full year 2025 results: US$1.70 loss per share (down from US$0.19 profit in FY 2024). Revenue: US$385.8m (down 36% from FY 2024). Net loss: US$18.7m (down US$20.8m from profit in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 51 percentage points per year, which is a significant difference in performance. Announcement • Feb 18
Medifast, Inc. Provides Earnings Guidance for the First Quarter of 2026 and Fiscal Year 2026 Medifast, Inc. provided earnings guidance for the first quarter of 2026 and fiscal year 2026. The company expects first quarter 2026 revenue to be in the range of $65 million to $80 million and first quarter 2026 loss per share to range from $0.15 to $0.70.
The company expects full year 2026 revenue to be in the range of $270 million to $300 million and full year 2026 loss per share to range from $1.55 to $2.75. Announcement • Feb 04
Medifast, Inc. to Report Q4, 2025 Results on Feb 17, 2026 Medifast, Inc. announced that they will report Q4, 2025 results After-Market on Feb 17, 2026 Announcement • Jan 31
Medifast, Inc. Declares Dividend, Payable on March 31, 2026 Medifast, Inc. announced a dividend of $1.00. The ex-dividend date is February 13, 2026, with a record date of February 18, 2026. The payment date for the dividend is scheduled for March 31, 2026. Announcement • Nov 14
Medifast Scientific & Clinical Affairs Team Showcases New Research in Metabolic Health At ObesityWeek Conference Medifast continues to lead the charge in addressing the growing health crisis of metabolic dysfunction by unveiling new research findings during ObesityWeek. Hosted by The Obesity Society in Atlanta, Georgia November 4-7, 2025, the annual conference for obesity researchers and clinicians centers on the latest developments in evidence-based obesity science: cutting-edge basic and clinical research, state-of-the-art obesity treatment and prevention and the latest efforts in advocacy and public policy. With a proud legacy of more than 40 years of clinical and scientific innovation, the Medifast Scientific and Clinical Affairs (S&CA) team continues to play a pivotal role in driving forward the understanding and management of metabolic health challenges. As part of the company's recently announced strategic transformation centered on metabolic health, Medifast's S&CA team presented two research studies that underscore its commitment to tackling metabolic dysfunction and promoting holistic health: "Mind the Plateau: Addressing Long-Term Weight Loss with Anti-Obesity Medications" - This study evaluates the long-term effects of GLP-1 medications, noting a weight loss plateau after 96 weeks of treatment with the highest dosage (15mg of Tirzepatide). It also reports a significant rebound in energy intake following medication discontinuation, leading to weight regain. Specifically, poor sleep quality increased the odds of obesity by 1.8 times and diabetes by 2.5 times over an average 12-year follow-up period. These findingsunderscore that sleep health should be considered alongside diet and physical activity as a core pillar of preventive health, healthy aging and optimal metabolic health. This research reinforces Medifast's broader business strategy introduced in October 2025 with the launch of Metabolic Synchronization™?, a breakthrough science that reverses metabolic dysfunction through a targeted reset of the body's metabolism. In addition to the conference presentations, Medifast Scientific Advisory Board member Dr. Jessica Unick, a Professor at Brown University and Senior Research Scientist at The Miriam Hospital's weight Control and Diabetes Research Center, co-authored a study alongside Medifast S&CA team members that explored predictors of weight loss. The study emphasized the importance of adherence and early intervention as key predictors of meaningful weight loss. With 30+ peer-reviewed studies, 70+ presentations and more than 40 years of clinical heritage, Medifast continues to set benchmarks for scientific rigor and innovation in the health and wellness industry. The S&CA team leads by example, leveraging their expertise at the crossroads of science and wellness to drive transformative change and support individuals on their wellness journeys. Reported Earnings • Nov 04
Third quarter 2025 earnings released: US$0.21 loss per share (vs US$0.10 profit in 3Q 2024) Third quarter 2025 results: US$0.21 loss per share (down from US$0.10 profit in 3Q 2024). Revenue: US$89.4m (down 36% from 3Q 2024). Net loss: US$2.26m (down 300% from profit in 3Q 2024). Revenue is expected to decline by 13% p.a. on average during the next 2 years, while revenues in the Personal Products industry in the United Kingdom are expected to grow by 2.7%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 37 percentage points per year, which is a significant difference in performance. Announcement • Nov 04
Medifast, Inc. Provides Earnings Guidance for the Fourth Quarter 2025 Medifast, Inc. provided earnings guidance for the fourth quarter 2025. The company expects fourth quarter 2025 revenue to be in the range of $65 million to $80 million and fourth quarter 2025 diluted loss per share to be in the range of $0.70 to $1.25. Announcement • Oct 27
Medifast, Inc. Announces Strategic Shift to Metabolic Health with the Introduction of Metabolic Synchronization Medifast, Inc. announced a strategic transformation, unveiling a new focus on holistic metabolic health. The company introduced Metabolic Synchronization™? -- a breakthrough science that reverses metabolic dysfunction with a targeted reset of the body's metabolism. Research shows the company's comprehensive system activates strong and targeted fat burn to improve metabolic health by reducing bad visceral fat, preserving lean mass and protecting muscle. This approach results in quality weight loss that goes beyond the scale, ultimately empowering individuals to reach their health goals. With nine in ten U.S. adults metabolically unhealthy, the country is facing a health crisis. Metabolic health -- often misunderstood or overlooked -- refers to the body's ability to efficiently convert food into energy, regulate critical body functions and maintain internal balance. Metabolic dysfunction is a state that can oftenently slip in and can put the body's metabolic processes under strain, cascading into some of today's most serious health challenges. Building on its legacy of transforming lives, Medifast is advancing its approach with Metabolic Synchronization™®?, a breakthrough science that reversales metabolic dysfunction with a targeted restart of the body's metabolism. This new science leverages years of clinical evidence to deliver results beyond the number on the scale. The first step of Metabolic Synchronization is quality weight loss. Recent breakthrough research shows the company's comprehensive system activate strong and targeted fat burn, driving measurable improvements in overall metabolic health and body composition through three key mechanisms: Burn: Targets visceral fat -- the bad fat stored around organs and muscles -- achieving a 14% reduction in vascular fat in just 16 weeks. Preserve: Helps retain 98% of lean mass, supporting strength, energy and mobility during weight loss. Protect: Supports healthy muscle to help restore the body's natural ability to improve an active metabolism, optimize energy use and regulate body weight. By focusing on the root causes of metabolic dysfunction, Medifast is unlocking new opportunities to reach and empower individuals at every stage of their health journey. For people utilizing weight loss medications, Medifast's programs provide complementary solutions to enhance metabolic function and overall health. For those pursuing a medication-free approach, the company's science-backed system offers an effective alternative, delivering measurable results through its holistic focus on metabolic health. Backed by Science, Driven by Innovation and Connection: With over 40 years of industry leadership, supported by 30+ peer-reviewed publications and clinical studies, Medifast remains committed to advancing science and innovation. The company's structured programs remain integral to this evolution, providing clients with a trusted foundation for metabolic health. Medifast also continues to stand apart with its human-centered approach. Clients who work with a personal coach experience 10 times greater weight loss and 17 times greater fat loss than those pursuing self-directed approaches+. Looking ahead, the company plans to launch new products using the science of metabolic synchronization in 2026, incorporating next-generation ingredients that further enhance metabolic health. Announcement • Oct 21
Medifast, Inc. to Report Q3, 2025 Results on Nov 03, 2025 Medifast, Inc. announced that they will report Q3, 2025 results After-Market on Nov 03, 2025 Announcement • Aug 05
Medifast, Inc. Provides Earnings Guidance for the Third Quarter 2025 Medifast, Inc. provided earnings guidance for the third quarter 2025. For the quarter, the company expects revenue to be in the range of $70 million to $90 million and diluted income/(loss) per share to be in the range of ($0.60) to $0.00. Reported Earnings • Aug 05
Second quarter 2025 earnings released: EPS: US$0.23 (vs US$0.75 loss in 2Q 2024) Second quarter 2025 results: EPS: US$0.23 (up from US$0.75 loss in 2Q 2024). Revenue: US$105.6m (down 37% from 2Q 2024). Net income: US$2.48m (up US$10.6m from 2Q 2024). Profit margin: 2.3% (up from net loss in 2Q 2024). Revenue is expected to decline by 14% p.a. on average during the next 2 years, while revenues in the Personal Products industry in the United Kingdom are expected to grow by 2.8%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 26 percentage points per year, which is a significant difference in performance. Announcement • Jul 22
Medifast, Inc. to Report Q2, 2025 Results on Aug 04, 2025 Medifast, Inc. announced that they will report Q2, 2025 results After-Market on Aug 04, 2025 New Risk • Jun 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 40% per year for the foreseeable future. Minor Risk Share price has been volatile over the past 3 months (8.2% average weekly change). Announcement • May 01
Medifast, Inc., Annual General Meeting, Jun 18, 2025 Medifast, Inc., Annual General Meeting, Jun 18, 2025. Location: 200 international drive, baltimore, maryland 21202, United States Reported Earnings • Apr 29
First quarter 2025 earnings released: US$0.071 loss per share (vs US$0.76 profit in 1Q 2024) First quarter 2025 results: US$0.071 loss per share (down from US$0.76 profit in 1Q 2024). Revenue: US$115.7m (down 34% from 1Q 2024). Net loss: US$772.0k (down 109% from profit in 1Q 2024). Revenue is expected to decline by 17% p.a. on average during the next 2 years, while revenues in the Personal Products industry in the United Kingdom are expected to grow by 2.4%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 6 percentage points per year, which is a significant difference in performance. Announcement • Apr 29
Medifast, Inc. Provides Earnings Guidance for the Second Quarter 2025 Medifast, Inc. provided earnings guidance for the second quarter 2025. The company expects second quarter 2025 revenue to be in the range of $85 million to $105 million and second quarter 2025 loss per share to be in the range of $0.00 to $0.55. Announcement • Apr 15
Medifast, Inc. to Report Q1, 2025 Results on Apr 28, 2025 Medifast, Inc. announced that they will report Q1, 2025 results After-Market on Apr 28, 2025 New Risk • Feb 20
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 0% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 92% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.3% net profit margin). New Risk • Feb 19
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 92% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 92% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Profit margins are more than 30% lower than last year (0.3% net profit margin). Announcement • Feb 19
Medifast, Inc. Provides Earnings Guidance for the First Quarter of 2025 Medifast, Inc. provided earnings guidance for the first quarter of 2025. The company expects first quarter 2025 revenue to be in the range of $100 million to $120 million and first quarter 2025 EPS to range from a loss of $0.50 per diluted share to $0.00 per diluted share. Reported Earnings • Feb 19
Full year 2024 earnings released: EPS: US$0.19 (vs US$9.13 in FY 2023) Full year 2024 results: EPS: US$0.19 (down from US$9.13 in FY 2023). Revenue: US$602.5m (down 44% from FY 2023). Net income: US$2.09m (down 98% from FY 2023). Profit margin: 0.3% (down from 9.3% in FY 2023). The decrease in margin was driven by lower revenue. Revenue is expected to decline by 9.8% p.a. on average during the next 2 years, while revenues in the Personal Products industry in the United Kingdom are expected to grow by 3.7%. Over the last 3 years on average, earnings per share has fallen by 52% per year whereas the company’s share price has fallen by 56% per year. Announcement • Feb 05
Medifast, Inc. to Report Q4, 2024 Results on Feb 18, 2025 Medifast, Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Feb 18, 2025 Announcement • Jan 07
Medifast Introduces New High-Protein Product Line OPTAVIA ASCEND for GLP-1 Users & Those Looking for Help to Keep Weight Off Medifast announced OPTAVIA ASCEND -- a new product line of high-protein, fiber-rich mini meals as well as a daily nutrient pack. These products are featured in two new science-backed nutrition plans designed for people on GLP-1 medications and those looking for help to keep weight off. The mini meals provide essential nutrients to promote muscle health, digestive health and bone health, and combined with the new plans and OPTAVIA's holistic offer, fill a critical gap in the weight management market. Medifast's launches OPTAVIA ASCEND - a new product line of high -protein, fiber-rich mini meal as well as a daily nutrient packs. These products are featured in a new science-backed nutrition plans Designed for people on GLP- 1 medications. GLP-1 medications are revolutionizing weight loss, but challenges remain. Studies show that two-thirds of weight lost on GLP-1 medications is typically regained within 12 months of stopping treatment, with cardiometabolic benefits often reversing as well. Additionally, muscle loss on GLP-1 medications can equal up to a decade worth of naturally occurring muscle loss within just 12-18 months, according to a recent scientific manuscript by Medifast published in Current Developments in Nutrition1. These findings highlight the importance of combining GLP-1 medications with proper nutrition and lifestyle habits, such as eating a protein-rich diet and incorporating regular resistance training to support skeletal muscle and metabolic health. New Risk • Dec 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.1% net profit margin). Valuation Update With 7 Day Price Move • Dec 16
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to US$17.83, the stock trades at a forward P/E ratio of 89x. Average forward P/E is 20x in the Personal Products industry in the United Kingdom. Total loss to shareholders of 91% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$24.62 per share. Buy Or Sell Opportunity • Dec 12
Now 21% undervalued Over the last 90 days, the stock has risen 11% to US$20.99. The fair value is estimated to be US$26.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 23% over the last 3 years. Earnings per share has declined by 39%. Revenue is forecast to decline by 24% in 2 years. Earnings are forecast to decline by 34% in the next 2 years. Reported Earnings • Nov 05
Third quarter 2024 earnings released: EPS: US$0.10 (vs US$2.12 in 3Q 2023) Third quarter 2024 results: EPS: US$0.10 (down from US$2.12 in 3Q 2023). Revenue: US$140.2m (down 41% from 3Q 2023). Net income: US$1.13m (down 95% from 3Q 2023). Profit margin: 0.8% (down from 9.8% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is expected to decline by 13% p.a. on average during the next 3 years, while revenues in the Personal Products industry in the United Kingdom are expected to grow by 3.3%. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings. Announcement • Nov 05
Medifast, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024 Medifast, Inc. provided earnings guidance for the fourth quarter of 2024. The Company expected revenue to be in the range of $100 million to $120 million and fourth quarter 2024 diluted loss per share to be in the range of $0.10 to $0.65. The EPS range excludes any gains or losses from changes in the market price of the company’s LifeMD common stock investment. Announcement • Oct 22
Medifast, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Medifast, Inc. announced that they will report Q3, 2024 results After-Market on Nov 04, 2024 New Risk • Aug 07
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 80% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 80% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Profit margins are more than 30% lower than last year (3.8% net profit margin). New Risk • Aug 06
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 3.8% Last year net profit margin: 9.7% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Profit margins are more than 30% lower than last year (3.8% net profit margin). Reported Earnings • Aug 06
Second quarter 2024 earnings released: US$0.75 loss per share (vs US$2.78 profit in 2Q 2023) Second quarter 2024 results: US$0.75 loss per share (down from US$2.78 profit in 2Q 2023). Revenue: US$168.6m (down 43% from 2Q 2023). Net loss: US$8.15m (down 127% from profit in 2Q 2023). Revenue is expected to decline by 20% p.a. on average during the next 2 years, while revenues in the Personal Products industry in the United Kingdom are expected to grow by 3.3%. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings. Announcement • Jul 23
Medifast, Inc. to Report Q2, 2024 Results on Aug 05, 2024 Medifast, Inc. announced that they will report Q2, 2024 results After-Market on Aug 05, 2024 Buy Or Sell Opportunity • Jul 03
Now 43% overvalued Over the last 90 days, the stock has fallen 41% to US$20.22. The fair value is estimated to be US$14.17, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.8% over the last 3 years. Earnings per share has declined by 12%. Revenue is forecast to decline by 27% in a year. Earnings are forecast to decline by 83% in the next year. Buy Or Sell Opportunity • Jul 02
Now 46% overvalued Over the last 90 days, the stock has fallen 38% to US$21.44. The fair value is estimated to be US$14.64, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.8% over the last 3 years. Earnings per share has declined by 12%. Revenue is forecast to decline by 27% in a year. Earnings are forecast to decline by 83% in the next year. Buy Or Sell Opportunity • Jul 01
Now 52% overvalued Over the last 90 days, the stock has fallen 38% to US$21.88. The fair value is estimated to be US$14.39, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.8% over the last 3 years. Earnings per share has declined by 12%. Revenue is forecast to decline by 27% in a year. Earnings are forecast to decline by 83% in the next year. Buy Or Sell Opportunity • Jun 19
Now 21% overvalued Over the last 90 days, the stock has fallen 43% to US$20.06. The fair value is estimated to be US$16.61, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.8% over the last 3 years. Earnings per share has declined by 12%. Revenue is forecast to decline by 27% in a year. Earnings are forecast to decline by 83% in the next year. Valuation Update With 7 Day Price Move • Jun 08
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to US$21.36, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 20x in the Personal Products industry in the United Kingdom. Total loss to shareholders of 92% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$16.29 per share. Valuation Update With 7 Day Price Move • May 06
Investor sentiment deteriorates as stock falls 24% After last week's 24% share price decline to US$26.58, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 20x in the Personal Products industry in the United Kingdom. Total loss to shareholders of 90% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$18.42 per share. New Risk • Apr 30
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 76% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 76% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Significant insider selling over the past 3 months (US$109k sold). Reported Earnings • Apr 30
First quarter 2024 earnings released: EPS: US$0.76 (vs US$3.68 in 1Q 2023) First quarter 2024 results: EPS: US$0.76 (down from US$3.68 in 1Q 2023). Revenue: US$174.7m (down 50% from 1Q 2023). Net income: US$8.32m (down 79% from 1Q 2023). Profit margin: 4.8% (down from 12% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is expected to decline by 17% p.a. on average during the next 2 years, while revenues in the Personal Products industry in the United Kingdom are expected to grow by 3.4%. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings. Buy Or Sell Opportunity • Apr 30
Now 22% overvalued Over the last 90 days, the stock has fallen 37% to US$35.10. The fair value is estimated to be US$28.79, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 5.8%. Announcement • Apr 30
Medifast, Inc. Provides Earnings Guidance for the Second Quarter of 2024 Medifast, Inc. provided earnings guidance for the second Quarter of 2024. The company expects second quarter 2024 revenue to be in the range of $150 million to $170 million and second quarter 2024 diluted EPS to be in the range of $0.05 to $0.40. The EPS range excludes the costs related to the initiation of the LifeMD collaboration and any gains or losses from changes in the market price of the company’s LifeMD common stock investment. Announcement • Apr 16
Medifast, Inc. to Report Q1, 2024 Results on Apr 29, 2024 Medifast, Inc. announced that they will report Q1, 2024 results After-Market on Apr 29, 2024 Valuation Update With 7 Day Price Move • Apr 05
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to US$32.58, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 19x in the Personal Products industry in Europe. Total loss to shareholders of 83% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$36.53 per share. Recent Insider Transactions • Mar 14
Independent Director recently sold US$109k worth of stock On the 8th of March, Scott Schlackman sold around 3k shares on-market at roughly US$39.46 per share. This transaction amounted to 37% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$482k more than they bought in the last 12 months. New Risk • Feb 22
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 63% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 63% per year for the foreseeable future. Minor Risk Share price has been volatile over the past 3 months (9.5% average weekly change). Reported Earnings • Feb 21
Full year 2023 earnings released: EPS: US$9.13 (vs US$12.82 in FY 2022) Full year 2023 results: EPS: US$9.13 (down from US$12.82 in FY 2022). Revenue: US$1.07b (down 33% from FY 2022). Net income: US$99.4m (down 31% from FY 2022). Profit margin: 9.3% (up from 9.0% in FY 2022). The increase in margin was driven by lower expenses. Revenue is expected to decline by 19% p.a. on average during the next 2 years, while revenues in the Personal Products industry in the United Kingdom are expected to grow by 3.5%. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 42% per year, which means it is performing significantly worse than earnings. Announcement • Feb 21
Medifast Provides Earnings Guidance for the First Quarter of 2024 Medifast provided earnings guidance for the first quarter of 2024. For the period, the company expects revenue to be in the range of $155 million to $175 million and diluted EPS to be in the range of $0.25 to $0.95. Announcement • Feb 07
Medifast, Inc. to Report Q4, 2023 Results on Feb 20, 2024 Medifast, Inc. announced that they will report Q4, 2023 results After-Market on Feb 20, 2024 Valuation Update With 7 Day Price Move • Jan 18
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to US$51.68, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 22x in the Personal Products industry in Europe. Total loss to shareholders of 74% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$54.93 per share. New Risk • Jan 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 33% per year for the foreseeable future. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.7% average weekly change). Buying Opportunity • Nov 07
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 23%. The fair value is estimated to be US$89.27, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 7.8%. Revenue is forecast to decline by 30% in 2 years. Earnings is forecast to decline by 33% in the next 2 years. Announcement • Nov 07
Medifast, Inc. Provides Earnings Guidance for the Full Year 2023 Medifast, Inc. provided earnings guidance for the full year 2023. For the year, the company expects revenue to be in the range of $1,050 million to $1,070 million and full-year 2023 diluted EPS to be in the range of $8.65to $9.55. New Risk • Oct 31
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$415k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 25% per year for the foreseeable future. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Significant insider selling over the past 3 months (US$415k sold). Announcement • Oct 24
Medifast, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Medifast, Inc. announced that they will report Q3, 2023 results After-Market on Nov 06, 2023 Announcement • Sep 14
Medifast, Inc. Announces Optavia Active Now Available Medifast announced its OPTAVIA ACTIVE line is now available to Customers, following a successful pre-launch to independent OPTAVIA Coaches in July 2023. The line, exclusively available on OPTAVIA.com when sign up to connect with an OPTAVIA Coach, includes OPTAVIA ACTIVE Essential Amino Acid (EAA) Blend and OPTAVIA ACTIVE Whey Protein, with additional products expected to be rolled out next year. The new line encourages the Habit of Healthy Motion, a key component of any health and wellness journey, and is scientifically designed to support muscle health. With more than one billion adults across the world not meeting the recommended guidelines for physical activity, the World Health Organization developed a global action plan to reduce physical inactivity by 15% by 20302. It's time to put the power of Community to work toward that goal. The new products work within existing OPTAVIA plans for those looking to achieve or maintain their optimal weight but also are a great solution for people wanting to enhance their health and wellbeing through movement. OPTAVIA ACTIVE products are backed by science, made with no colors, flavors or sweeteners from artificial sources and are Informed Sport certified - a global standard in sports nutrition quality control that ensures its certified products contain no banned substances. Through the app, users have access to more than 8,000 on-demand, guided workouts across 15+ class categories and 60+ fitness and wellness programs as well as a global community feed where they will find further advice and support. The company's proprietary OPTAVIA app has also been updated to include features supporting the new ACTIVE platform, including an integrated motion tracker. The app is designed to help OPTAVIA Customers track and document their health journey and offers a convenient resource to guide Customers on their paths to a healthier lifestyle. Now through October 31, 2023, Customers can save $10.00 on the purchase of up to three OPTAVIA ACTive products, for a maximum of $30.00 savings, in addition to $7.00 flat rate shipping with the purchase of two or moreOPTAVIA ACTIVE products. Announcement • Sep 08
Medifast, Inc. Declares Quarterly Cash Dividend, Payable on November 7, 2023 Medifast, Inc. announced that its Board of Directors has declared a $1.65 quarterly cash dividend to its stockholders. The quarterly cash dividend is payable on November 7, 2023, to stockholders of record as of the close of business on September 19, 2023. Announcement • Aug 09
Medifast, Inc. Provides Earnings Guidance for the Third Quarter 2023 Medifast, Inc. provided earnings guidance for the third quarter 2023. For the period, the company expects revenue to be in the range of $220 million to $240 million and third quarter 2023 diluted EPS to be in the range of $0.71 to $1.32. Reported Earnings • Aug 08
Second quarter 2023 earnings released: EPS: US$2.78 (vs US$3.45 in 2Q 2022) Second quarter 2023 results: EPS: US$2.78 (down from US$3.45 in 2Q 2022). Revenue: US$296.2m (down 35% from 2Q 2022). Net income: US$30.3m (down 23% from 2Q 2022). Profit margin: 10% (up from 8.6% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is expected to decline by 24% p.a. on average during the next 2 years, while revenues in the Personal Products industry in the United Kingdom are expected to grow by 3.3%. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Announcement • Jul 28
Medifast Unveils New Product Line, Optavia Active Medifast unveiled a new product line, OPTAVIA ACTIVE. The line includes premium exercise supplements and protein powders, OPTAVIA ACTive Essential Amino Acid (EAAs) Blend and OPTAVIA ACTIVE Whey Protein, with other products expected to be rolled out next year. Both are designed to help new and existing Customers of all fitness levels optimize their motion habits. OPTAVIA ACTIVE marks an inflection point for the company, as it targets new Customer segments and triples its total addressable market by entering the sports nutrition category - a $30 billion market. Formulated to work with or without OPTAVIA nutrition plans and guided by Coach support, OPTAVIA ACTives is backed by science, made with no colors, flavors or sweeteners from artificial sources and is Informed Sport certified -- a global standard in sports nutrition quality control that ensures its certified products contain no banned substances. OPTAVIA A ACTIVE EAAs contain a clinically studied blend of eighessential amino acids, including an imprpressive 3.5 grams of leucine per serving, specifically designed to help activate muscle protein synthesis -- the natural process where protein is produced to repair or build new muscle. OPTAVIA ACTive Whey Protein contains 24 grams of high-quality, complete protein per serving, and when paired with a healthy diet and exercise plan, can help build muscle and strength. As pt ofof this new healthy motion program, the company has partnered with Aaptiv, a leading fitness app, to provide on-demand, guided workouts for its Community. Announcement • Jul 25
Medifast, Inc. to Report Q2, 2023 Results on Aug 07, 2023 Medifast, Inc. announced that they will report Q2, 2023 results After-Market on Aug 07, 2023 Buying Opportunity • Jul 22
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 2.6%. The fair value is estimated to be US$117, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to decline by 23% in a year. Earnings is forecast to decline by 37% in the next year. Buying Opportunity • Jun 28
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 9.9%. The fair value is estimated to be US$115, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to decline by 23% in a year. Earnings is forecast to decline by 37% in the next year. Announcement • Jun 16
Medifast, Inc. Declares Quarterly Cash Dividend, Payable on August 8, 2023 Medifast, Inc. announced that its Board of Directors has declared a $1.65 quarterly cash dividend to its stockholders. The quarterly cash dividend of $1.65 per share is payable on August 8, 2023, to stockholders of record as of the close of business on June 27, 2023. Announcement • May 26
Medifast, Inc., Annual General Meeting, Jun 14, 2023 Medifast, Inc., Annual General Meeting, Jun 14, 2023, at 16:30 US Eastern Standard Time. Location: The Four Seasons Baltimore, 200 International Drive, Baltimore Maryland United States Agenda: To elect seven nominees to the Board of Directors to serve for a one-year term expiring in 2024; to ratify the appointment of RSM US LLP as the independent registered public accounting firm of the company for the fiscal year ending December 31, 2023; to approve, on an advisory basis, the compensation of the company's named executive officers; to approve, on an advisory basis, the frequency of the advisory vote on executive compensation; and to transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof. 
